Bristol Myers Squibb Focuses on Oncology and Immunology to Counter Upcoming Patent Expirations

NodeGuardian

2026-03-20 13:45:20

Abstract generation in progress

Bristol Myers Squibb is proactively addressing anticipated patent expirations for several key drugs by implementing a robust pipeline strategy. The company is intensifying its focus on oncology, immunology, cardiovascular diseases, and hematology through expanded research and development efforts. This strategic shift aims to introduce innovative therapies and sustain revenue despite upcoming patent cliffs.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes